Compare SYRE & DKL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SYRE | DKL |
|---|---|---|
| Founded | 2013 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Natural Gas Distribution |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.4B |
| IPO Year | 2016 | N/A |
| Metric | SYRE | DKL |
|---|---|---|
| Price | $34.16 | $53.07 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 1 |
| Target Price | ★ $56.50 | $45.00 |
| AVG Volume (30 Days) | ★ 569.5K | 64.5K |
| Earning Date | 02-26-2026 | 02-27-2026 |
| Dividend Yield | N/A | ★ 8.77% |
| EPS Growth | N/A | ★ 9.17 |
| EPS | N/A | ★ 3.09 |
| Revenue | N/A | ★ $967,420,000.00 |
| Revenue This Year | N/A | $11.84 |
| Revenue Next Year | N/A | $10.46 |
| P/E Ratio | ★ N/A | $16.60 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.91 | $34.59 |
| 52 Week High | $35.31 | $53.52 |
| Indicator | SYRE | DKL |
|---|---|---|
| Relative Strength Index (RSI) | 57.61 | 62.33 |
| Support Level | $30.92 | $50.31 |
| Resistance Level | $34.07 | $53.52 |
| Average True Range (ATR) | 1.80 | 1.39 |
| MACD | -0.03 | 0.19 |
| Stochastic Oscillator | 78.41 | 72.49 |
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
Delek Logistics Partners LP owns and operates logistics and marketing assets for crude oil and intermediate and refined products. The company's segment includes gathering and processing; wholesale marketing and terminalling; storage and transportation and investment in pipeline joint ventures. It generates maximum revenue from the wholesale marketing and terminalling segment, which provides marketing services for the refined products output of the Delek Holdings' refineries, engages in wholesale activity at its terminals and terminals owned by third parties, whereby it purchases light product for sale and exchange to third parties, and provides terminalling services at its refined products terminals to independent third parties and Delek Holdings.